OptimizeRx
OPRX· Services· Fiscal year ends in December
Stephen Silvestro is the CEO of OptimizeRx and was paid $2.7M in FY2025 (Dec), up 179%.
Executives3
See all- 1Stephen SilvestroChief Executive OfficerFY2025
- 2Theresa GrecoChief Commercial OfficerFY2025
- 3Edward StelmakhChief Financial & Strategy OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allOptimizeRx paid its 3 named executives $5.8M in total in FY2025 (Dec). CEO Stephen Silvestro was paid $2.7M of that.
| Name | |||
|---|---|---|---|
| Stephen SilvestroChief Executive Officer | |||
| Theresa GrecoChief Commercial Officer | Not disclosed | Not disclosed | |
| Edward StelmakhChief Financial & Strategy Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers16
See allThe FY2025 (Dec) proxy of OptimizeRx names 16 peer companies for pay. Among OptimizeRx and these peers, CEO pay was the lowest of 2 and total shareholder return was the lowest of 2.
2nd highest of 2in OptimizeRx and its pay peers, FY2025 (Dec) by CEO pay:
2nd highest of 2in OptimizeRx and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Lynn O’Connor VosChair · 10 yr on the boardIndependentAudit, Compensation, Nominating and Governance, Strategic—Paid as an executive
- James LangDirector · 8 yr on the boardIndependentCompensation (Chair), Nominating and Governance—Paid as an executive
- Patrick SpanglerDirector · 7 yr on the boardIndependentAudit (Chair), Compensation, Strategic—Paid as an executive
- Gregory WassonDirector · 5 yr on the boardIndependentCompensation, Strategic—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Apr 15, 2024 | FY2023 |